Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tegavivint · BC-2059

Small molecule · Inhibitor of transducin beta-like protein 1 (TBL1XR1) · developed by Iterion Therapeutics

Phase 1/2 Most advanced trial
1 Registered trials

What is Tegavivint?

Tegavivint is a small molecule inhibitor of the Wnt/beta-catenin pathway. It binds transducin beta-like protein 1 (TBL1), disrupting its binding to beta-catenin, which promotes beta-catenin degradation and reduces TCF4-driven transcription. It is being studied in hepatocellular carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BC-2059
Drug type
Small molecule
Targets
transducin beta-like protein 1 (TBL1XR1), beta-catenin (CTNNB1) (binding partner it blocks)
Mechanism
Inhibitor of transducin beta-like protein 1 (TBL1XR1)
Pathways
Wnt/beta-catenin signaling, TCF4 transcriptional activity, cyclin D1, c-Myc and survivin expression
Therapy area
Oncology
Developer
Iterion Therapeutics
In trials of
EXEL
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
18AP231HUP

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07878689 Phase 1/2 Hepatocellular Carcinoma (HCC) Not yet recruiting EXEL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hepatocellular Carcinoma (HCC)

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.